Last reviewed · How we verify
Biocon's Human Insulin R U-500 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Biocon's Human Insulin R U-500 (Biocon's Human Insulin R U-500) — Biocon Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Biocon's Human Insulin R U-500 TARGET | Biocon's Human Insulin R U-500 | Biocon Limited | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Biocon's Human Insulin R U-500 CI watch — RSS
- Biocon's Human Insulin R U-500 CI watch — Atom
- Biocon's Human Insulin R U-500 CI watch — JSON
- Biocon's Human Insulin R U-500 alone — RSS
Cite this brief
Drug Landscape (2026). Biocon's Human Insulin R U-500 — Competitive Intelligence Brief. https://druglandscape.com/ci/biocon-s-human-insulin-r-u-500. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab